Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT Dose Escalation with Gemcitabine in Pancreatic Cancer
NCT00593866Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2006
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in pancreatic cancer (PC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Maximum Tolerated Radiation Dose at 13 weeks. Started Jun 2006; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00593866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00593866.